INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis

FRA:IUI1 • US46120E6023

416.25 EUR
+11.5 (+2.84%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

7

Overall IUI1 gets a fundamental rating of 7 out of 10. We evaluated IUI1 against 65 industry peers in the Health Care Equipment & Supplies industry. IUI1 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IUI1 shows excellent growth, but is valued quite expensive already. These ratings could make IUI1 a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year IUI1 was profitable.
  • IUI1 had a positive operating cash flow in the past year.
  • IUI1 had positive earnings in each of the past 5 years.
  • IUI1 had a positive operating cash flow in each of the past 5 years.
IUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFIUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

1.2 Ratios

  • The Return On Assets of IUI1 (13.96%) is better than 90.63% of its industry peers.
  • IUI1 has a Return On Equity of 16.02%. This is amongst the best in the industry. IUI1 outperforms 82.81% of its industry peers.
  • IUI1 has a Return On Invested Capital of 13.95%. This is amongst the best in the industry. IUI1 outperforms 89.06% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for IUI1 is above the industry average of 9.57%.
  • The last Return On Invested Capital (13.95%) for IUI1 is above the 3 year average (12.43%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROIC 13.95%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
IUI1.DE Yearly ROA, ROE, ROICIUI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • IUI1's Profit Margin of 28.38% is amongst the best of the industry. IUI1 outperforms 95.31% of its industry peers.
  • In the last couple of years the Profit Margin of IUI1 has grown nicely.
  • IUI1 has a better Operating Margin (29.35%) than 96.88% of its industry peers.
  • IUI1's Operating Margin has improved in the last couple of years.
  • The Gross Margin of IUI1 (66.00%) is better than 73.44% of its industry peers.
  • In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
Industry RankSector Rank
OM 29.35%
PM (TTM) 28.38%
GM 66%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
IUI1.DE Yearly Profit, Operating, Gross MarginsIUI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IUI1 is creating some value.
  • The number of shares outstanding for IUI1 has been reduced compared to 1 year ago.
  • Compared to 5 years ago, IUI1 has more shares outstanding
  • There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IUI1.DE Yearly Shares OutstandingIUI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
IUI1.DE Yearly Total Debt VS Total AssetsIUI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

2.2 Solvency

  • IUI1 has an Altman-Z score of 41.84. This indicates that IUI1 is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of IUI1 (41.84) is better than 100.00% of its industry peers.
  • There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 41.84
ROIC/WACC1.4
WACC9.98%
IUI1.DE Yearly LT Debt VS Equity VS FCFIUI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 4.87 indicates that IUI1 has no problem at all paying its short term obligations.
  • IUI1 has a better Current ratio (4.87) than 95.31% of its industry peers.
  • IUI1 has a Quick Ratio of 3.96. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
  • IUI1 has a Quick ratio of 3.96. This is amongst the best in the industry. IUI1 outperforms 93.75% of its industry peers.
Industry RankSector Rank
Current Ratio 4.87
Quick Ratio 3.96
IUI1.DE Yearly Current Assets VS Current LiabilitesIUI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.83%, which is quite impressive.
  • The Earnings Per Share has been growing by 21.42% on average over the past years. This is a very strong growth
  • Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 20.51%.
  • Measured over the past years, IUI1 shows a quite strong growth in Revenue. The Revenue has been growing by 18.22% on average per year.
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.00% on average over the next years. This is quite good.
  • Based on estimates for the next years, IUI1 will show a quite strong growth in Revenue. The Revenue will grow by 12.91% on average per year.
EPS Next Y14.46%
EPS Next 2Y14.31%
EPS Next 3Y14.59%
EPS Next 5Y14%
Revenue Next Year15.92%
Revenue Next 2Y14.87%
Revenue Next 3Y14.63%
Revenue Next 5Y12.91%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IUI1.DE Yearly Revenue VS EstimatesIUI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
IUI1.DE Yearly EPS VS EstimatesIUI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • IUI1 is valuated quite expensively with a Price/Earnings ratio of 55.28.
  • Based on the Price/Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 60.94% of the companies are valued more cheaply.
  • IUI1's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.68.
  • Based on the Price/Forward Earnings ratio of 48.31, the valuation of IUI1 can be described as expensive.
  • 70.31% of the companies in the same industry are cheaper than IUI1, based on the Price/Forward Earnings ratio.
  • IUI1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 55.28
Fwd PE 48.31
IUI1.DE Price Earnings VS Forward Price EarningsIUI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than 67.19% of the companies in the same industry.
  • IUI1's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 70.4
EV/EBITDA 45.89
IUI1.DE Per share dataIUI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of IUI1 may justify a higher PE ratio.
  • IUI1's earnings are expected to grow with 14.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.82
PEG (5Y)2.58
EPS Next 2Y14.31%
EPS Next 3Y14.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IUI1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INTUITIVE SURGICAL INC

FRA:IUI1 (2/13/2026, 7:00:00 PM)

416.25

+11.5 (+2.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22
Earnings (Next)04-20
Inst Owners88.29%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap147.82B
Revenue(TTM)10.06B
Net Income(TTM)2.86B
Analysts78.1
Price Target533.68 (28.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.28%
Min EPS beat(2)9.85%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)10.81%
Min EPS beat(4)3.05%
Max EPS beat(4)18.71%
EPS beat(8)8
Avg EPS beat(8)11.52%
EPS beat(12)12
Avg EPS beat(12)8.73%
EPS beat(16)14
Avg EPS beat(16)6.39%
Revenue beat(2)2
Avg Revenue beat(2)2.19%
Min Revenue beat(2)2.17%
Max Revenue beat(2)2.22%
Revenue beat(4)4
Avg Revenue beat(4)1.83%
Min Revenue beat(4)1.09%
Max Revenue beat(4)2.22%
Revenue beat(8)5
Avg Revenue beat(8)1.43%
Revenue beat(12)7
Avg Revenue beat(12)0.96%
Revenue beat(16)9
Avg Revenue beat(16)0.46%
PT rev (1m)1.93%
PT rev (3m)2.36%
EPS NQ rev (1m)0.17%
EPS NQ rev (3m)0.31%
EPS NY rev (1m)3%
EPS NY rev (3m)3.32%
Revenue NQ rev (1m)0.53%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)1.01%
Revenue NY rev (3m)1.05%
Valuation
Industry RankSector Rank
PE 55.28
Fwd PE 48.31
P/S 17.42
P/FCF 70.4
P/OCF 57.86
P/B 9.84
P/tB 10.06
EV/EBITDA 45.89
EPS(TTM)7.53
EY1.81%
EPS(NY)8.62
Fwd EY2.07%
FCF(TTM)5.91
FCFY1.42%
OCF(TTM)7.19
OCFY1.73%
SpS23.89
BVpS42.31
TBVpS41.39
PEG (NY)3.82
PEG (5Y)2.58
Graham Number84.67
Profitability
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROCE 16.01%
ROIC 13.95%
ROICexc 20.73%
ROICexgc 21.4%
OM 29.35%
PM (TTM) 28.38%
GM 66%
FCFM 24.75%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
ROICexc(3y)18.4%
ROICexc(5y)18.81%
ROICexgc(3y)19.07%
ROICexgc(5y)19.65%
ROCE(3y)14.27%
ROCE(5y)14.28%
ROICexgc growth 3Y2.03%
ROICexgc growth 5Y0.92%
ROICexc growth 3Y2.86%
ROICexc growth 5Y2.05%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 79.72%
Cap/Sales 5.36%
Interest Coverage 250
Cash Conversion 83.46%
Profit Quality 87.21%
Current Ratio 4.87
Quick Ratio 3.96
Altman-Z 41.84
F-Score8
WACC9.98%
ROIC/WACC1.4
Cap/Depr(3y)178.7%
Cap/Depr(5y)155.64%
Cap/Sales(3y)11.2%
Cap/Sales(5y)9.67%
Profit Quality(3y)61.68%
Profit Quality(5y)71.87%
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
EPS Next Y14.46%
EPS Next 2Y14.31%
EPS Next 3Y14.59%
EPS Next 5Y14%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
Revenue Next Year15.92%
Revenue Next 2Y14.87%
Revenue Next 3Y14.63%
Revenue Next 5Y12.91%
EBIT growth 1Y25.34%
EBIT growth 3Y22.76%
EBIT growth 5Y22.63%
EBIT Next Year34.54%
EBIT Next 3Y22.15%
EBIT Next 5Y17.41%
FCF growth 1Y91.03%
FCF growth 3Y37.49%
FCF growth 5Y16.85%
OCF growth 1Y25.49%
OCF growth 3Y26.68%
OCF growth 5Y15.34%

INTUITIVE SURGICAL INC / IUI1.DE FAQ

Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?

ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE.


Can you provide the valuation status for INTUITIVE SURGICAL INC?

ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.


Can you provide the profitability details for INTUITIVE SURGICAL INC?

INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 9 / 10.


Can you provide the financial health for IUI1 stock?

The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 9 / 10.